Complete financial analysis of MGC Pharmaceuticals Limited (MGCLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MGC Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) Income Statement Analysis – Financial Results
- Tarmat Limited (TARMAT.BO) Income Statement Analysis – Financial Results
- Air France-KLM SA (AFLYY) Income Statement Analysis – Financial Results
- Third Age Health Services Limited (TAH.NZ) Income Statement Analysis – Financial Results
- BankFinancial Corporation (BFIN) Income Statement Analysis – Financial Results
MGC Pharmaceuticals Limited (MGCLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://mgcpharma.com.au
About MGC Pharmaceuticals Limited
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39M | 4.65M | 2.96M | 2.03M | 656.24K | 296.81K | 120.24K | 2.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Cost of Revenue | 1.94M | 3.01M | 1.65M | 1.90M | 356.64K | 119.34K | 158.07K | 15.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.45M | 1.63M | 1.31M | 130.15K | 299.60K | 177.47K | -37.83K | -12.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Gross Profit Ratio | 42.82% | 35.15% | 44.23% | 6.40% | 45.65% | 59.79% | -31.46% | -583.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.99M | 4.24M | 5.86M | 5.37M | 2.87M | 951.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.13M | 8.28M | 5.73M | 6.61M | 2.61M | 3.36M | 4.27M | 683.09K | 510.09K | 244.11K | 362.77K | 101.01K | 98.33K | 1.43M | 1.70M | 1.39M | 1.03M | 0.00 |
| Selling & Marketing | 926.91K | 949.83K | 583.19K | 562.13K | 574.98K | 612.76K | 204.76K | 240.26K | 36.39K | 12.33K | 9.38K | 3.16K | 4.83K | 223.63K | 326.02K | 477.93K | 462.40K | 0.00 |
| SG&A | 13.06M | 9.23M | 6.31M | 6.61M | 3.19M | 3.97M | 4.47M | 923.35K | 546.48K | 256.43K | 372.16K | 104.17K | 103.17K | 1.65M | 2.03M | 1.86M | 1.49M | 0.00 |
| Other Expenses | -578.77K | -1.18M | -425.12K | 524.32K | 9.46M | -1.79M | -1.29M | -1.78M | -6.51K | 1.60K | -27.35K | 15.00K | 28.39K | 951.09K | 155.02K | 27.97K | 2.59M | 0.00 |
| Operating Expenses | 17.05M | 15.08M | 13.38M | 12.55M | 9.34M | 7.44M | 7.28M | 4.36M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Cost & Expenses | 24.26M | 18.10M | 15.03M | 14.45M | 9.70M | 7.56M | 7.44M | 4.38M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Interest Income | 240.00 | 300.00 | 7.63K | 12.34K | 201.85K | 191.59K | 127.26K | 46.03K | 5.89K | 7.10K | 25.66K | 38.06K | 7.12K | 759.08K | 390.37K | 27.97K | 40.94K | 0.00 |
| Interest Expense | 257.40K | 190.05K | 369.14K | 135.58K | 8.00K | 99.37K | 19.72K | 120.01K | 0.00 | 0.00 | 0.00 | 0.00 | 95.14K | 1.74M | 573.54K | 11.34K | 25.89K | 0.00 |
| Depreciation & Amortization | 751.94K | 504.30K | 491.41K | 481.13K | 259.74K | 328.11K | 83.52K | 16.58K | 0.00 | 0.00 | 8.33K | 0.00 | 0.00 | 166.64K | 35.47K | 47.60K | 40.48K | 0.00 |
| EBITDA | -14.69M | -15.16M | -12.00M | -13.04M | -8.45M | -8.54M | -8.40M | -6.09M | -3.80M | -5.35M | -756.87K | -343.94K | -216.95K | -855.93K | -1.34M | -1.57M | -55.88K | 0.00 |
| EBITDA Ratio | -455.34% | -303.90% | -404.87% | -443.15% | 134.22% | -2,875.65% | -6,984.90% | -277,354.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -243.40% | -63.32% | -82.21% | -2.13% | 0.00% |
| Operating Income | -15.23M | -14.63M | -12.49M | -9.50M | 621.07K | -8.86M | -8.48M | -6.11M | -3.80M | -5.35M | -765.21K | -343.94K | -216.95K | -1.02M | -1.37M | -1.61M | -96.37K | 0.00 |
| Operating Income Ratio | -449.72% | -314.75% | -421.46% | -466.80% | 94.64% | -2,986.19% | -7,054.36% | -278,109.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -290.78% | -65.00% | -84.70% | -3.67% | 0.00% |
| Total Other Income/Expenses | -5.90M | -1.64M | -1.59M | -7.48M | 6.84M | -1.94M | -1.21M | -2.01M | -166.94K | -2.65K | -27.35K | 53.06K | -232.49K | -2.16M | -573.54K | -11.34K | 14.60K | 0.00 |
| Income Before Tax | -21.13M | -17.14M | -13.53M | -18.81M | -1.88M | -8.99M | -8.50M | -6.23M | -3.80M | -5.34M | -766.90K | -290.88K | -449.44K | -3.18M | -1.95M | -1.63M | -81.77K | 0.00 |
| Income Before Tax Ratio | -623.80% | -368.81% | -456.71% | -924.70% | -285.93% | -3,029.02% | -7,070.76% | -283,571.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -904.30% | -92.17% | -85.30% | -3.11% | 0.00% |
| Income Tax Expense | 2.02K | -1.36M | -27.28K | 1.21M | 27.32K | -1.04K | -1.63M | -1.73M | 0.00 | 0.00 | -25.66K | 0.00 | -117.28K | 2.14M | 728.55K | 251.84K | 2.57M | 0.00 |
| Net Income | -20.82M | -16.77M | -13.97M | -19.36M | -2.31M | -8.25M | -8.14M | -6.16M | -3.80M | -5.34M | -766.90K | -290.88K | 1.94M | -2.63M | -1.95M | -1.88M | -81.77K | 0.00 |
| Net Income Ratio | -614.71% | -360.79% | -471.33% | -951.67% | -351.91% | -2,778.31% | -6,773.31% | -280,252.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -748.06% | -92.17% | -98.51% | -3.11% | 0.00% |
| EPS | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.40 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| EPS Diluted | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.37 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| Weighted Avg Shares Out | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.81K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
| Weighted Avg Shares Out (Dil) | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.96K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
MGC Pharmaceuticals partners begin long-Covid study using ArtemiC Support
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said a clinical study is underway to assess the potential of its supplement ArtemiC Support to treat people with long-Covid. Partners Swiss PharmaCan (TSX-V:MJN) and Glow LifeTech are carrying out the research which should...
MGC Pharmaceuticals raises £5.5mln to fund emergency use authorisation for Covid treatment
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it has raised £5.5mln via a share placing – cash that will be used to fund emergency use authorisation applications for the use of its lead asset in Covid. It said it plans...
MGC Pharmaceuticals completes production of ArtemiC A$1 million order for global distributor Swiss PharmaCan
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has completed production of a A$1 million order of ArtemiCTM for leading European nutraceuticals distributor Swiss PharmaCan (TSX-V:MJN) AG (SPC) and is now ready to deliver the order. Under the terms of the agreement, the full purchase...
MGC Pharmaceuticals receives full cash deposit from AMC for CimertrA order
MGC Pharmaceutical Ltd said it received the full US$750,00 cash deposit from AMC Holdings Inc under the companies' three-year US$24mln US supply and distribution deal. The cash deposit is pre-payment on AMC's recent US$3mln purchase order for CimetrA, MGC's curcumin...
MGC Pharmaceuticals receives full cash deposit from AMC for CimertrA order
MGC Pharmaceutical Ltd said it received the full US$750,00 cash deposit from AMC Holdings Inc under the companies' three-year US$24mln US supply and distribution deal. The cash deposit is pre-payment on AMC's recent US$3mln purchase order for CimetrA, MGC's curcumin...
MGC Pharmaceuticals' Malta facility completed on time and to budget
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said a new facility in Malta that will be used to produce its potentially breakthrough plant-based COVID-19 treatment has been completed on time and to budget. The plan is to immediately begin the equipment...
MGC Pharmaceuticals gets the regulatory green light to start dosing Covid patients
MGC Pharmaceuticals Ltd said the Israeli authorities have approved a dosing study of its phytomedicine CimetrA for use in treating the effects of COVID-19. In all, 240 people will be recruited to arrive at the optimum regimen for the Curcumin...
MGC Pharmaceuticals posts record sales after strong quarter
MGC Pharmaceuticals Ltd rose on Tuesday after updating investors on its activities during the quarter. The September and June quarters combined have delivered a record US$2.2mln in cash sales receipts for a consecutive six-month period, with increasing month on month...
MGC Pharmaceuticals advances phase 3 clinical trial of CimetrA for the treatment of COVID-19
MGC Pharmaceuticals Ltd is currently undertaking a phase 3 clinical trial of CimetrA in Israel as an investigational medicinal product for the treatment of COVID-19 following successful phase 2 trials in 2020. COVID-19 pandemic − clinical challenges CimetrA is a...
MGC Pharmaceuticals says AMC Holdings places first order under US$24mln supply deal
MGC Pharmaceuticals Ltd said its partner AMC Holdings has placed its first order a little over a month after signing the supply deal worth up to US$24mln over the next three years. The US$3mln purchase order is for CimetrA, MGC's...
Source: https://incomestatements.info
Category: Stock Reports